In this Q&A, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, examines how clinical ...

In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, offers a ...

In today's ACT Brief, we examine Veristat's acquisition of Certara's regulatory business, why reimbursement probability ...

Sites can strengthen their position by approaching feasibility strategically, investing in clear communication, and being ...

The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...

Seventeen placebo-controlled trials across seven antibodies yielded statistically significant but clinically small mean ...

In today's ACT Brief, we explore organizational factors behind CRL decisions, methodological concerns with pooling amyloid ...

Oral semaglutide lowered HbA1c vs placebo in a phase 3 trial in adolescents with type 2 diabetes, pending full data and ...

In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, makes the case ...

Veristat has announced its intended acquisition of Certara's Regulatory and Medical Writing business, a move that will add ...

Partner at Global Life Sciences Alliance (GLSA) and brings over 30 years of experience in the life sciences and clinical research industry. He has worked extensively across research sites, CROs, and ...

In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, explains why ...